**
A remarkable medical advancement has transformed the life of a six-year-old girl from Stevenage, who has regained her sight thanks to innovative gene therapy. Saffie Sandford, who suffers from Leber’s Congenital Amaurosis (LCA), underwent a pioneering treatment at Great Ormond Street Hospital (GOSH). Her mother, Lisa, described the momentous change as akin to having a “magic wand” waved over her daughter’s vision, which had been severely compromised by this genetic condition.
Understanding Leber’s Congenital Amaurosis
Leber’s Congenital Amaurosis is a rare inherited disorder that leads to significant vision loss from infancy. It occurs due to mutations that inhibit the production of vital proteins necessary for proper eye function. As a result, individuals with LCA typically experience poor vision in daylight and complete blindness in low-light conditions. Without intervention, the prognosis for those affected can be dire; Lisa Sandford revealed that doctors had warned them Saffie could be entirely blind by the time she reached adulthood.
Saffie was diagnosed with LCA at the age of five, following a period during which her parents noted her increasing difficulty in seeing in dim light. Until then, she had been wearing glasses since she was two, initially misdiagnosed with myopia. The family’s journey through this shocking diagnosis and the subsequent search for treatment has been described by Lisa as a “rollercoaster.”
The Gene Therapy Treatment
The pioneering treatment Saffie received, known as Luxturna, was administered at GOSH and is notable for being the first of its kind to address specific genetic causes of LCA. The therapy involves a one-time injection of a healthy copy of the gene directly into each eye. Saffie underwent two procedures, one eye treated in April 2025 and the other in September of the same year.
According to GOSH, this therapy is not a cure but represents a significant step forward in managing the condition. It aims to enhance visual pathways during critical stages of brain development, particularly in younger patients like Saffie. Research conducted by scientists at GOSH and University College London indicates that children receiving the therapy show varying degrees of improvement based on their age at the time of treatment.
Positive Outcomes and Continuing Research
Rob Henderson, a consultant ophthalmologist at GOSH, noted that the results of the therapy have been “incredible,” with Saffie demonstrating marked improvements in her peripheral vision during daylight. The clinical trials monitored 15 children between the ages of 15 months and 12 years who received the gene therapy between 2020 and 2023. Findings suggested that younger children exhibited more substantial improvements compared to their older counterparts, reinforcing the importance of timing in the administration of this therapy.
Additionally, the research team employed pattern visual evoked potentials—an objective, painless test that measures signal transmission from the retina to the brain—to assess the therapy’s effectiveness. The outcomes of these assessments have illuminated the potential of gene therapy to enrich the quality of life for children grappling with inherited retinal diseases.
Why it Matters
This breakthrough in gene therapy not only highlights the potential for significant advancements in the treatment of genetic eye conditions but also underscores the importance of early intervention. For families like the Sandfords, the ability to restore sight brings a profound sense of relief and hope. As medical science continues to evolve, such treatments could redefine the futures of countless children affected by similar conditions, paving the way for a brighter and more visually enriched life. The implications extend beyond individual cases, signalling a new era in public health where genetic therapies may soon become standard practice in combating inherited diseases.
